Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $16.63 and traded as low as $15.00. Seres Therapeutics shares last traded at $15.18, with a volume of 60,238 shares traded.

Wall Street Analyst Weigh In

MCRB has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price target on Seres Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Seres Therapeutics has a consensus rating of “Reduce” and an average price target of $14.33.

Seres Therapeutics Stock Performance

The business’s fifty day moving average price is $16.63 and its two-hundred day moving average price is $16.54. The stock has a market capitalization of $137.38 million, a P/E ratio of -4.25 and a beta of 0.22.

Hedge Funds Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MCRB. Goldman Sachs Group Inc. increased its position in shares of Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 21,679 shares during the last quarter. Invesco Ltd. raised its stake in shares of Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 89,995 shares during the period. Bank of America Corp DE lifted its holdings in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 5,157 shares during the last quarter. XTX Topco Ltd bought a new position in Seres Therapeutics during the 2nd quarter valued at about $249,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Seres Therapeutics in the 3rd quarter worth about $557,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.